Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

X
Trial Profile

A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Mesna; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications Acute biphenotypic leukaemia; Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by Mayo Clinic record.
    • 05 Mar 2013 Planned End Date changed from 1 Sep 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 24 Dec 2012 New source identified and integrated (Mayo Clinic record, 11-007469).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top